NASDAQ:EIKN Eikon Therapeutics Q1 2026 Earnings Results & Report $6.77 +0.05 (+0.71%) As of 09:45 AM Eastern This is a fair market value price provided by Massive. Learn more. Eikon Therapeutics missed analyst earnings expectations in its Q1 2026 results, released May 11, 2026. The company reported EPS of -$2.46 versus the -$1.47 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 11, 2026TimeAfter Market ClosesConference Call4:00 PM ET Eikon Therapeutics EPS ResultsActual EPS-$2.46Consensus EPS -$1.47Beat/MissMissed by -$0.99One Year Ago EPSN/AEikon Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eikon Therapeutics Q1 2026 Earnings FAQ Did Eikon Therapeutics beat earnings estimates for Q1 2026? Eikon Therapeutics (NASDAQ:EIKN) reported earnings of -$2.46 per share for Q1 2026, missing the consensus estimate of -$1.47. The report was announced on Monday, May 11, 2026. Eikon Therapeutics Earnings HeadlinesEikon Therapeutics Stock: Will Upcoming ESMO Data Rekindle Investor Interest?September 23, 2026 | rttnews.comEikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 14 at 1:00 AM | Paradigm Press (Ad)Inhibrx, Eikon rise after insider buyingSeptember 9, 2026 | msn.comMajor Investor Makes Bold Move on Eikon Therapeutics SharesSeptember 8, 2026 | tipranks.comEikon Therapeutics Appoints Ching-Pin Chang As Executive VP & Chief Scientific OfficerSeptember 3, 2026 | rttnews.comSee More Eikon Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eikon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eikon Therapeutics and other key companies, straight to your email. Email Address About Eikon TherapeuticsEikon Therapeutics (NASDAQ:EIKN) is a biotechnology company focused on discovering and developing medicines using advanced single-molecule imaging, cell biology and computational technologies. Its platform is designed to track the behavior of proteins and other molecular targets in living cells, with the goal of improving the understanding of disease biology and identifying potential drug candidates. The company is developing a pipeline of therapeutics, including investigational treatments in areas such as oncology and other serious diseases. Eikon’s technology is intended to support drug discovery, target validation and the development of therapies designed to address disease mechanisms at the molecular level. The company does not currently market a broad portfolio of commercial products. Eikon Therapeutics was founded in 2019 and is headquartered in the San Francisco Bay Area of California. The company was established with participation from scientist and physician Rick Klausner, and Roger D. Perlmutter has served as its chief executive officer. Eikon’s research and development activities are primarily based in the United States.View Eikon Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
